Compounds for treating krass mutant tumors and uses thereof

Compound 666-15 achieves selective killing of KRAS mutant cells by targeting SLC25A51 and SDH, solving the targeting and toxicity problems in existing technologies and providing an effective treatment option for KRAS mutant tumors.

CN122127243APending Publication Date: 2026-06-02FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
FUDAN UNIVERSITY
Filing Date
2026-01-27
Publication Date
2026-06-02

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to compounds for treating KRAS-mutant tumors and their uses. This invention provides compound 666-15, which provides dual inhibition of cytoplasmic-mitochondrial NAD5. + Transport (via targeting SLC25A51) and succinate dehydrogenase (SDH / complex II), while simultaneously disrupting mitochondrial NAD. + Transport and respiratory chain NAD + A novel therapeutic strategy to target KRAS-mutant tumors by utilizing regenerative functions.
Need to check novelty before this filing date? Find Prior Art